Markets:

Overview

News

Currencies

International

Treasuries

Compass Therapeutics, Inc. - Common Stock (NQ:CMPX)

1.960 +0.190 (+10.73%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Compass Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

On Wednesday, there are stocks with unusual volume. Let's take a look. ↗

April 29, 2026

Via Chartmill

These stocks are moving in today's session ↗

April 27, 2026

Via Chartmill

Monday's session: most active stocks ↗

April 27, 2026

Via Chartmill

Top stock movements in today's session. ↗

April 27, 2026

Via Chartmill

These stocks are gapping in today's session ↗

April 27, 2026

Via Chartmill

Top movers in Monday's pre-market session ↗

April 27, 2026

Via Chartmill

Top movers in Friday's after hours session ↗

April 24, 2026

Via Chartmill

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗

March 21, 2026

This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.

Via The Motley Fool

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.

Via The Motley Fool

Topics Regulatory Compliance

The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

January 14, 2026

Issued on behalf of Oncolytics Biotech Inc.

From USA News Group

Via GlobeNewswire

Compass Therapeutics Inc (NASDAQ:CMPX) Reports Wider Q2 2025 Loss, Shares Show Mixed Reaction Amid Clinical Progress ↗

August 11, 2025

Compass Therapeutics reports Q2 2025 results with a wider-than-expected loss but shows progress in clinical trials for oncology treatments. Market reacts mixedly.

Via Chartmill

Compass Therapeutics Posts Wider Q2 Loss ↗

August 11, 2025

Via The Motley Fool

Topics Intellectual Property

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Top movers in Wednesday's session ↗

April 02, 2025

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Via Chartmill

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer ↗

April 01, 2025

Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced biliary tract cancer patients.

Via Benzinga

What's going on in today's after hours session ↗

March 31, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 31, 2025

Via Benzinga

This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

February 24, 2025

Via Benzinga

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

February 19, 2025

Via Benzinga

Top 3 High-Momentum Companies Analysts Are Still Bullish On

February 04, 2025

Momentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.

Via MarketBeat

CMPX Stock Earnings: Compass Therapeutics Meets EPS for Q2 2024 ↗

August 12, 2024

CMPX stock results show that Compass Therapeutics met analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 10, 2024

Via Benzinga

CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024 ↗

May 13, 2024

CMPX stock results show that Compass Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 01, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 26, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 25, 2024

Via Benzinga

3 Penny Stocks With the Power to 10X Your $1K Investment ↗

March 24, 2024

The 10X penny stocks discussed here are a much more reliable investment than many other alternatives investors are likely to encounter.

Via InvestorPlace

CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023 ↗

March 21, 2024

CMPX stock results show that Compass Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 05, 2024

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.